2/1/2022 6:23:00 AM
Reviva Pharma Doses First Patients In Phase 3 Study Evaluating Brilaroxazine For Schizophrenia
1/10/2022 6:23:41 AM
Reviva Pharma Gets FDA Clearance To Proceed With Initiation Of Pivotal Phase 3 Trial Of Brilaroxazine For Schizophrenia
8/16/2021 8:28:33 AM
Reviva Pharma Q2 Net Loss $2.6 Mln Or $0.23/Shr Vs Loss $1.6 Mln Or $0.58/Shr Last Year
5/26/2021 8:47:52 PM
Reviva Announces Pricing Of Upsized $30 Mln Underwritten Public Offering